Hoth Therapeutics’ (HOTH) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report released on Thursday,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Separately, Wall Street Zen upgraded shares of Hoth Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 31st. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Hoth Therapeutics has a consensus rating of “Buy” and an average price target of $4.00.

Hoth Therapeutics Trading Down 8.5%

HOTH stock opened at $1.30 on Thursday. The firm has a 50-day moving average price of $0.93 and a 200-day moving average price of $1.03. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The stock has a market capitalization of $17.17 million, a P/E ratio of -0.98 and a beta of 0.55.

Hoth Therapeutics (NASDAQ:HOTH) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.07. As a group, equities analysts predict that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC increased its holdings in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 15.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,946 shares of the company’s stock after buying an additional 13,038 shares during the period. Geode Capital Management LLC owned about 1.39% of Hoth Therapeutics worth $72,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.